Figure 4.

Activation of D₂R inhibited the A_2AR-mediated beneficial effects in vivo. Transgenic mice (A315T TDP-43) and littermate control mice (non-transgenic mice; NTG) and were treated with T1-11 (0.25 mg/ml) or vehicle (1% DMSO) in the drinking water and co-treated with QP (6 mg/kg) or saline by intraperitoneal injection from the age of 7 weeks (N = 5–7). (A) Spinal cords from the indicated mice were harvested to examine PKA activity at the age of 10 weeks (N = 5–7). (B,C) Spinal cord sections from the indicated mice, aged of 10 weeks, were stained with a human-TDP-43 (green) and a ChAT (red) antibodies (N = 3). Representative images are shown in (B), and the quantified results are presented in (C). At least 40 motor neurons were scored in each group. The yellow arrow indicates TDP-43 located in the nucleus, and the white arrow indicates TDP-43 mislocalization. Scale bar: 10 μm. (D) Relative grip strength was examined after treatment with the indicated drug(s) in A315T TDP-43 mice at the age of 10 weeks. ^*p < 0.05, significantly different between the indicated groups. n.s., not significant.